Dr. Litton on the EMBRACA Trial in Advanced BRCA1/2+ Breast Cancer

Jennifer K. Litton, MD, associate professor in the Department of Breast Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses the phase 3 EMBRACA trial in patients with germline BRCA1/2-mutated metastatic HER2-negative breast cancer. 

The EMBRACA trial is the largest trial of PARP monotherapy to date, says Litton. In this international study, patients were randomized 2:1 to receive either talazoparib (Talzenna) once daily or ​physician's choice chemotherapy.

Initial findings from the study showed a 3-month progression-free survival improvement with talazoparib compared with chemotherapy, says Litton.

Updated findings presented at the 2020 AACR Virtual Annual Meeting revealed that the PARP inhibitor did not demonstrate a statistically significant overall survival benefit versus chemotherapy in this patient population.